Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors
Body composition refers to the proportional content of body fat mass and lean body mass that can lead to a continuum of different phenotypes ranging from cachectic/sarcopenic state to obesity. The heterogenetic phenotypes of body composition can contribute to formation of some cancer types and can s...
Main Authors: | Karam Khaddour, Sandra L. Gomez-Perez, Nikita Jain, Jyoti D. Patel, Yanis Boumber |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-10-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2020.576314/full |
Similar Items
-
Characteristics of patients with lung cancer in clinical practice and their potential eligibility for clinical trials evaluating tyrosine kinase inhibitors or immune checkpoint inhibitors
by: Abtahi, S., et al.
Published: (2022) -
Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies
by: Karam Khaddour, et al.
Published: (2021-06-01) -
Mechanisms of acquired resistance to tyrosine kinase inhibitors
by: Yi-fan Chen, et al.
Published: (2011-12-01) -
Inhibitory effects of regorafenib, a multiple tyrosine kinase inhibitor, on corneal neovascularization
by: Halil Ibrahim Onder, et al.
Published: (2014-04-01) -
Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review
by: Vito Longo, et al.
Published: (2019-04-01)